Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Basic Clin Pharmacol Toxicol ; 119(6): 540-547, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27194111

RESUMEN

The compound 5-fluorouracil (5-FU) is used in cancer chemotherapy and is known to cause diarrhoea. We recently reported that chemokine (C-X-C motif) ligand 1 (CXCL1) and neutrophils in the colonic mucosa were markedly increased by the administration of 5-FU in mice. Curcumin has anti-inflammatory, antitumour and antioxidant properties. Therefore, we examined the effect of curcumin on 5-FU-induced diarrhoea development and CXCL1 and CXCL2 up-regulation in the colon. Mice were given 5-FU (50 mg/kg, i.p.) daily for 4 days. Curcumin (100 or 300 mg/kg, p.o.) was administered on the day before the first administration of 5-FU and administered 30 min. before the administration of 5-FU. Gene expression levels of CXCL1 and CXCL2 in the colon were examined by real-time RT-PCR. Curcumin reduced the 5-FU-induced diarrhoea development. Under this condition, the CXCL1 and CXCL2 gene up-regulated by 5-FU administration was inhibited by curcumin. The gene expression of CXCL1 and CXCL2 was also enhanced by 5-FU application in vitro. The 5-FU-induced up-regulated CXCL1 and CXCL2 gene expressions were inhibited by curcumin, Bay-117082 and bortezomib, nuclear factor kappa B (NF-κB) inhibitors, C646, a p300/cyclic adenosine monophosphate response element-binding protein-histone acetyltransferase (HAT) inhibitor. In conclusion, these findings suggested that curcumin prevented the development of diarrhoea by inhibiting NF-κB and HAT activation.


Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Antioxidantes/uso terapéutico , Colon Descendente/efectos de los fármacos , Curcumina/uso terapéutico , Diarrea/prevención & control , Suplementos Dietéticos , Fluorouracilo/efectos adversos , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Antimetabolitos Antineoplásicos/química , Antimetabolitos Antineoplásicos/farmacología , Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Quimiocina CXCL1/agonistas , Quimiocina CXCL1/antagonistas & inhibidores , Quimiocina CXCL1/genética , Quimiocina CXCL1/metabolismo , Quimiocina CXCL2/agonistas , Quimiocina CXCL2/antagonistas & inhibidores , Quimiocina CXCL2/genética , Quimiocina CXCL2/metabolismo , Colon Descendente/inmunología , Colon Descendente/metabolismo , Colon Descendente/fisiopatología , Curcumina/administración & dosificación , Curcumina/farmacología , Diarrea/inducido químicamente , Diarrea/metabolismo , Diarrea/fisiopatología , Proteína p300 Asociada a E1A/agonistas , Proteína p300 Asociada a E1A/antagonistas & inhibidores , Proteína p300 Asociada a E1A/metabolismo , Inhibidores Enzimáticos/farmacología , Fluorouracilo/antagonistas & inhibidores , Fluorouracilo/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/fisiopatología , Masculino , Ratones Endogámicos C57BL , FN-kappa B/agonistas , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Índice de Severidad de la Enfermedad , Técnicas de Cultivo de Tejidos
2.
J Pharm Pharmacol ; 62(3): 389-92, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20487224

RESUMEN

OBJECTIVES: Intestinal bacteria are thought to be involved in the initiation and perpetuation of inflammatory bowel diseases. Prebiotics (non-digestable dietary carbohydrate) have beneficial properties that alter the intestinal flora and contain glutamine-rich protein. Glutamine significantly decreases indices of inflammation. In this study, an enzymatic hydrolysate of corn gluten (EHCG) was administered by gavage to Sprague-Dawley rats fed an elemental diet to determine whether EHCG can ameliorate experi- mental colitis. METHODS: Colitis was induced by intrarectal administration of 2,4,6-trinitrobenzene sulfonic acid after 10 days' daily oral administration of EHCG at 100 and 300 mg/kg. Macroscopic damage was assessed using a scoring system. The mucosa homogenate was sonicated and myeloperoxidase activity and histamine levels measured. KEY FINDINGS: Treatment with EHCG significantly decreased the severity of injury and reduced myeloperoxidase activity and histamine levels in the distal colon mucosa. CONCLUSIONS: EHCG may have therapeutic benefit as a supplement in enteral nutrition for patients with inflammatory bowel diseases.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Colitis/prevención & control , Glútenes/metabolismo , Hidrolisados de Proteína/uso terapéutico , Semillas/química , Zea mays/química , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Colitis/inducido químicamente , Colitis/patología , Colon Descendente/efectos de los fármacos , Colon Descendente/metabolismo , Colon Descendente/patología , Suplementos Dietéticos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Alimentos Formulados/efectos adversos , Histamina/metabolismo , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Masculino , Peroxidasa/metabolismo , Hidrolisados de Proteína/administración & dosificación , Ratas , Ratas Sprague-Dawley , Índice de Severidad de la Enfermedad , Ácido Trinitrobencenosulfónico/toxicidad
3.
Int J Pharm ; 286(1-2): 41-52, 2004 Nov 22.
Artículo en Inglés | MEDLINE | ID: mdl-15501001

RESUMEN

The aim of this study was to determine whether the duration of ischemia affects antipyrine absorption in the large intestine. This was carried out in a rat model of ischemic colitis in which ischemia and associated inflammation was induced by marginal vessel ligation. Blood flow was disrupted by positioning an o-ring around the distal rectum and ligating the marginal vessel at two locations in the hind-gut ligament artery region. Ligation was performed for 1, 2, 3, and 5h. We assessed large intestine damage by measuring key indicators of inflammation, myeloperoxidase (MPO) activity and thiobarbituric acid reactant substrates (TBARS) in the mucosa and by histological staining with hematoxylin-eosin stain. Antipyrine membrane permeability was assessed in Ussing-type diffusion chambers, and related pharmacokinetics were calculated from antipyrine plasma concentration measurements following colon administration of the drug. Vessel ligation caused some sloughing of epithelial cells and elevated the MPO and TBARS levels. Prolonged ligation failed to affect the apparent permeability coefficient (P(app)) of antipyrine. Prolonged ligation, however, gradually increased plasma antipyrine concentrations to near control levels. This increase was paralleled by increases in the absorption rate constant AUC and antipyrine bioavailability. Taken together, these results suggest that the absorption kinetics of antipyrine may depend on blood flow changes in the large intestine that occur with inflammation.


Asunto(s)
Antipirina/metabolismo , Permeabilidad de la Membrana Celular/efectos de los fármacos , Colitis Isquémica/metabolismo , Modelos Animales de Enfermedad , Animales , Antipirina/administración & dosificación , Antipirina/farmacocinética , Área Bajo la Curva , Disponibilidad Biológica , Permeabilidad de la Membrana Celular/fisiología , Colitis Isquémica/tratamiento farmacológico , Colitis Isquémica/patología , Colon Descendente/efectos de los fármacos , Colon Descendente/metabolismo , Colon Descendente/ultraestructura , Evaluación Preclínica de Medicamentos/métodos , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/patología , Inyecciones Intravenosas , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/ultraestructura , Japón , Ligadura/métodos , Masculino , Peroxidasa/metabolismo , Ratas , Ratas Wistar , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo
4.
Int Immunopharmacol ; 3(13-14): 1731-41, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14636824

RESUMEN

In this study, we have evaluated the efficacy of dosmalfate, a new flavonoid derivative compound, for the prevention and treatment of experimental colitis. To induce colitis, BALB/c mice received 5% dextran sulphate sodium (DSS) in their drinking water continuously for 7 days. Colitis was quantified by a clinical damage score, colon length, weight loss, stool consistency and rectal bleeding. Inflammatory response was assessed by neutrophil infiltration, determined by histology and myeloperoxidase (MPO) activity. Interleukin (IL)-1 beta, prostaglandins (PG)E(2) and (PG)D(2) concentrations in colonic tissue, histological and histochemical analysis of the lesions were also measured. Dosmalfate (400-800 mg/kg body weight, p.o.) ameliorated severe colitis reduced the degree of inflammation through reduction of neutrophil infiltration and IL-1 beta levels. (PG)E(2) and (PG)D(2) synthesis were significantly reduced in colitis control group and treatment with dosmalfate abolished the decrease in PG synthesis in colon mucosa. We conclude that dosmalfate is protective in acute DSS-induced colitis. The beneficial effects seem to be related to a decrease of neutrophil infiltration, absence of up-regulation of IL-1 beta and increase of PG production in colon mucosa.


Asunto(s)
Colitis Ulcerosa/inducido químicamente , Sulfato de Dextran/efectos adversos , Sulfato de Dextran/antagonistas & inhibidores , Diosmina/análogos & derivados , Diosmina/uso terapéutico , Administración Oral , Animales , Colitis Ulcerosa/tratamiento farmacológico , Colon Descendente/efectos de los fármacos , Colon Descendente/lesiones , Colon Descendente/ultraestructura , Colon Transverso/efectos de los fármacos , Colon Transverso/lesiones , Colon Transverso/ultraestructura , Sulfato de Dextran/administración & dosificación , Dinoprostona/biosíntesis , Diosmina/administración & dosificación , Diosmina/farmacocinética , Modelos Animales de Enfermedad , Ingestión de Líquidos , Flavonoides/administración & dosificación , Flavonoides/química , Flavonoides/farmacocinética , Interleucina-1/biosíntesis , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/enzimología , Mucosa Intestinal/lesiones , Masculino , Ratones , Ratones Endogámicos BALB C , Infiltración Neutrófila/efectos de los fármacos , Peroxidasa/metabolismo , Prostaglandina D2/biosíntesis , Factores de Tiempo , Agua
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA